Scrip M&A Podcast: Why Has M&A Activity Ramped Downward In 2024?
Scrip’s Joseph Haas discusses biopharma M&A topics such as why deal activity declined during Q2 and Q3 with Gerardo Ubaghs of Frontier Medicines and Jason Silvers of Generate Biomedicines